🔗 Share this article

As the US undertakes historic changes to its vaccine guidelines, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by expressing skepticism about Covid shots in the global health crisis and has focused upon potential deaths following COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Scheduled Shifts to Pediatric Immunization Schedule

Health officials were set to reveal radical revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US out of step with a large portion of the international standard with no evidence for benefit. The planned update has been postponed until the coming year.

Rather than the top vaccines chief, Høeg is set to speak at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

A Shift at the Agency

This interim role might represent a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the agency – and it signals a increased emphasis upon reevaluating long-standing immunizations at the FDA.

Høeg has frequently advocated for halting some pediatric shot schedules in the US so as to align more like Denmark, a society with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

So far comments, she has kept her attention on vaccination policy – traditionally the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Expertise

Dr. Høeg has no obvious track record in pharmaceutical research, approval processes or administrative roles, which has been standard for previous leaders of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in managing a major agency. She lacks background in pharmaceutical oversight.”

Previous commissioners of the center would “understand laws and regulations and the science of medication creation”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who ran the center have had.”

CDER has an enormous workload at the FDA, the former commissioner stated.

“Many people just zeroes in on the innovative therapies, but the off-patent medication office authorizes a multitude of generic medications. There is also a biosimilars program, non-prescription drug unit and more, and each of these need to be managed,” she said. “The area you neglect, that is the part that I always told people is going to bite you.”

Additionally, a significant leadership aspect to the role, which supervises in excess of 5,000 staff members. “It is a massive management job, if you perform it correctly,” she added.

Response and Contentious Policies

Regarding inquiries about Dr. Høeg's fitness for the role and whether this assignment signifies greater collaboration among FDA leaders on vaccines, a spokesperson responded that the “questions rely on flawed premises”.

“Her resume aligns with the duties of her role,” the spokesperson said, noting the time Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a disputed rapid medication authorization process that allegedly concerned her former heads. “By what process are these therapies being selected for this expedited pathway? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of secrecy happening at the agency right now.”

In general, he said, “the FDA appears to be shifting towards laxer oversight of most medications, except for shots.”

Established Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if problematic, history, Howard observe. She released a analysis using non-validated public submissions to estimate the incidence of heart inflammation after Covid immunization. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccinations are more dangerous than they are.

Part of her “wish list” for the new federal leadership encompassed changing regulations for new vaccines and halting “non-essential” immunizations, she said following the vote on a online show. At the agency, Dr. Høeg has allegedly floated the idea of barring adolescent males from getting Covid vaccinations.

“She’s an all-around ideologue who starts off with her conclusions and reverse-engineers to accommodate the evidence in a highly deceptive, fraudulent way,” Howard said.

Taking Control and a “Revenge Tour”

Høeg became part of other skeptics, {like|